Clinical Report
Comparison on the efficacy between the intravitreal injection of aflibercept and ranibizumab for the treatment of wet age-related macular degeneration
Shen Zhansheng, Chen Mengping
Published 2022-01-05
Cite as Chin J Ocul Traum Occupat Eye Dis, 2022, 44(1): 38-42. DOI: 10.3760/cma.j.cn116022-20210821-00302
Abstract
ObjectiveTo compare the clinical efficacy between intravitreal injection of aflibercept and ranibizumab for the treatment of wet age-related macular degeneration (AMD).
MethodsThis was a prospective randomized controlled study.Total of 79 eyes of 79 cases of wet AMD from Apr.to Jun.2019 in Zhengzhou Second People’s Hospital were randomly divided into two groups.In the aflibercept group, 39 eyes of 39 cases received intravitreal injection of aflibercept.In the ranibizumab group, 40 eyes of 40 cases received intravitreal injection of ranibizumab.The treatment efficacy between the two groups was compared at 6 months and 12 months after operation.
ResultsAt 6 and 12 months after operapation, BCVA of the two groups were better than those preoperatively (t=5.680, 5.310; all P<0.001), but there was no significant difference in BCVA between the two groups (t=1.420, 1.066; P=0.160, 0.290). The central macular thickness(CMT) after operation in the two groups were lower than those before operation (t=6.900, 7.499; all P<0.001), but there was no significant difference between the two groups (t=0.262, 0.412; P=0.794, 0.681). The average number of injections in the aflibercept group was (7.63±1.25) times, which was less than the (8.72±1.62) times in the ranibizumab group (t=-3.342, P=0.002).
ConclusionIntravitreal injection of aflibercept or ranibizumab can both reduce the CMT in the treatment of wet AMD and improve visual acuity.Aflibercept is injected less frequently.
Key words:
Degeneration, macular, age-related, wet; Aflibercept; Ranibizumab; Thickness, central, macular; Acuity, visual
Contributor Information
Shen Zhansheng
Department of Ophthalmology, The Second People’s Hospital of Zhengzhou, Zhengzhou Institute of Ophthalmology, Zhengzhou 450000, China
Chen Mengping
Department of Ophthalmology, The Second People’s Hospital of Zhengzhou, Zhengzhou Institute of Ophthalmology, Zhengzhou 450000, China
